We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. “In this final follow-up from the SIMPLICITY HTN-3 trial ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. WASHINGTON — In patients with treatment-resistant ...

A radiofrequency-based renal denervation system for uncontrolled hypertension got a cool reception from FDA advisors who nevertheless left the door open for regulatory approval. On Wednesday, the ...

National coverage analysis is the first-of-its kind for a minimally invasive, interventional treatment for high blood pressure Milestone is supported by large public health need and robust, long-term ...

Evidence from trials designed and launched after release of the disappointing results of SYMPLICITY HTN-3 supports renal denervation as a third major option for the treatment of hypertension alongside ...

Company commits to advancing clinical data for Symplicity™ with the SPYRAL Gemini clinical trial and expansion of the GSR-DEFINE clinical trial "These findings are a key step toward informing the ...

PARIS, France—Patients who spend the most time with optimally controlled blood pressure after renal denervation have a lower rate of major cardiovascular events than do those with less-than-ideal ...

Renal denervation delivers radiofrequency energy to overactive nerves in renal arteries and branch vessels. Renal denervation along with use of antihypertensive drugs leads to a sustained reduction in ...

Kidney denervation, a procedure where the nerves in renal arteries are burned, may be a future treatment for people whose blood pressure remains high despite medication use. Results from the ...

Medtronic and Recor Medical stand to benefit from national Medicare coverage for their new device-based treatments for patients with uncontrolled high blood pressure. Medtronic and Recor have had ...

“Radiofrequency renal denervation compared with sham control produced a clinically meaningful and lasting blood pressure reduction up to 36 months of follow-up, independent of concomitant ...